BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther 2017;45:455-67. [PMID: 27910116 DOI: 10.1111/apt.13882] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Bradley-Stewart A, Goldstein E, MacLean A, Gunson R. Prevalence of pre-treatment hepatitis C virus NS5A resistance associated amino-acid substitutions in genotype 1A infected patients in Scotland. J Clin Virol 2018;101:44-6. [PMID: 29414187 DOI: 10.1016/j.jcv.2018.01.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dasbach EJ, Elbasha EH. Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview. Pharmacoeconomics 2017;35:673-83. [PMID: 28456972 DOI: 10.1007/s40273-017-0508-2] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
3 Corman S, Elbasha EH, Michalopoulos SN, Nwankwo C. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. Value in Health 2017;20:1110-20. [DOI: 10.1016/j.jval.2017.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
4 Yuen MF, Liu SH, Seto WK, Mak LY, Corman SL, Hsu DC, Lee MYK, Khan TK, Puenpatom A. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. Dig Dis Sci 2021;66:1315-26. [PMID: 32385703 DOI: 10.1007/s10620-020-06281-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Eckman MH, Ward JW, Sherman KE. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. Clin Gastroenterol Hepatol 2019;17:930-939.e9. [PMID: 30201597 DOI: 10.1016/j.cgh.2018.08.080] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
6 Liu J, Zhang Y, Wu B, Wang S, Bin-Chia Wu D, You R. Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China. Front Pharmacol 2021;12:717504. [PMID: 34721016 DOI: 10.3389/fphar.2021.717504] [Reference Citation Analysis]
7 Cipriano LE, Goldhaber-Fiebert JD. Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy Pract 2018;3:2381468318776634. [PMID: 30288448 DOI: 10.1177/2381468318776634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
8 Brandão R, Marcelino R, Gonçalves F, Diogo I, Carvalho A, Cabanas J, Costa I, Brogueira P, Ventura F, Miranda A, Mansinho K, Gomes P. Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. Viruses 2018;10:E223. [PMID: 29701642 DOI: 10.3390/v10050223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
9 Hernández-Conde M, Fernández I, Perelló C, Gallego A, Bonacci M, Pascasio JM, Romero-Gómez M, Llerena S, Fernández-Rodríguez C, Castro Urda JL, García Buey L, Carmona I, Morillas RM, García ND, Gea F, Carrión JA, Castellote J, Moreno-Planas JM, Piqueras Alcol B, Molina E, Diago M, Montoliu S, de la Vega J, Menéndez F, Sánchez Ruano JJ, García-Samaniego J, Rosales-Zabal JM, Anton MD, Badia E, Souto-Rodríguez R, Salmeron FJ, Fernández-Bermejo M, Figueruela B, Moreno-Palomares JJ, Calleja JL. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort. J Viral Hepat 2019;26:55-64. [PMID: 30265418 DOI: 10.1111/jvh.13008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
10 Crespo J, Cuadrado A, Perelló C, Cabezas J, Llerena S, Llorca J, Cedillo S, Llop E, Escudero MD, Hernández Conde M, Puchades L, Redondo C, Fortea JI, Gil de Miguel A, Serra MA, Lazarus JV, Calleja JL. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. J Viral Hepat 2020;27:360-70. [PMID: 31755634 DOI: 10.1111/jvh.13238] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
11 Fawsitt CG, Vickerman P, Cooke GS, Welton NJ; STOP HCV Consortium. Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. Value Health 2020;23:180-90. [PMID: 32113623 DOI: 10.1016/j.jval.2019.08.012] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Liu J, Guo M, Ke L, You R. Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review. Front Public Health 2022;10:836986. [DOI: 10.3389/fpubh.2022.836986] [Reference Citation Analysis]